KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Amortization - Intangibles (2016 - 2025)

Pfizer (PFE) has disclosed Amortization - Intangibles for 17 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles changed N/A to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $4.9 billion for FY2025, 7.79% down from the prior year.
  • Amortization - Intangibles for Q4 2025 was $1.2 billion at Pfizer, up from $1.2 billion in the prior quarter.
  • The five-year high for Amortization - Intangibles was $1.3 billion in Q3 2024, with the low at $822.0 million in Q3 2022.
  • Average Amortization - Intangibles over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2023.
  • The sharpest move saw Amortization - Intangibles decreased 15.08% in 2022, then surged 44.04% in 2023.
  • Over 5 years, Amortization - Intangibles stood at $968.0 million in 2021, then fell by 15.08% to $822.0 million in 2022, then soared by 54.14% to $1.3 billion in 2023, then increased by 3.55% to $1.3 billion in 2024, then decreased by 6.25% to $1.2 billion in 2025.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $1.2 billion, $1.2 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.